drug
Rare Disease
Preclinicalupdated 6mo agoby Dawn Sea Therapeutics
Preclinicalcommunity read0 votes
🐶 often sniffed alongside
top 8- tagOncology6 co-mentions · 2 sources
- tagRare Disease5 co-mentions · 5 sources
- tagPulmonology2 co-mentions · 2 sources
- tagNSCLC2 co-mentions · 2 sources
- drugSL-9012 co-mentions · 2 sources
- drugUndisclosed2 co-mentions · 2 sources
- companyStemline Therapeutics Inc2 co-mentions · 2 sources
- companyJohns Hopkins University1 co-mentions · 1 sources
all catalysts(2)
News(10)
- Sanofi gains FDA clearance for Gaucher disease pillThe approval culminates a winding development journey for Infilbray, and provides Sanofi with a new source of income ahead of Dupixent’s looming patent expiration.biopharma_dive · 5h ago
- nChroma halves workforce, BioXcel lets execs goFollow along as BioSpace tracks job cuts and restructuring initiatives.biospace · 7h ago
- Regeneron racks up another first as FDA greenlights generalized myasthenia gravis RNA drugThe go-ahead for Alnylam Pharmaceuticals–licensed Livsayis marks Regeneron’s second new modality this year after the company secured approval for hearing loss gene therapy Otarmeni in April.biospace · 7h ago
- Sanofi secures first FDA approval to treat neurological symptoms in rare metabolic diseaseSanofi’s Infilbray is designed to cross the blood-brain barrier, allowing the drug to prevent the toxic buildup of disease-causing lipids in the brain for patients with type 3 Gaucher disease.biospace · 8h ago
- Ramping up: 3 biotechs growing their workforce after series C raisesBiotechs that announced series C financing this year and are hiring include one that secured $140 million and has locations in London and Massachusetts.biospace · 18h ago
- White House pulls nomination for FDA nominee OvertonThe sudden end of Heidi Overton’s candidacy likely ensures a Democrat-controlled Congress will choose the FDA’s next leader — but shouldn’t disrupt the agency, analysts say.biopharma_dive · 1d ago
- CTAD 2026: Biogen, AriBio lead the way in slowing cognitive decline in Alzheimer’sBiogen and AriBio reported wins for their respective therapies targeting Alzheimer’s disease, while Priavoid and Cognito Therapeutics missed the mark—though the latter plans to file for FDA approva…biospace · 1d ago
- Summit’s rejection, Isomorphic’s record $5B raise, obesity and Alzheimer’s in the spotlightThe FDA declined to approve Summit Therapeutics’ Akeso-partnered ivonescimab, putting other PD-1/VEGF drug developers on notice; Isomorphic bagged a $5 billion series C, the largest in biotech hist…biospace · 1d ago
- 5 acquisitions that forced Big Pharmas to co-parentAcquiring a biotech with an existing Big Pharma partner can impose financial and strategic constraints around data sharing and milestone and royalty payments—but it is “rarely a deal-breaker,” acco…biospace · 1d ago
- White House yanks Overton nomination hours before committee voteThe Trump administration withdrew the nomination of Heidi Overton for FDA commissioner Tuesday evening, reportedly due to opposition from Republican Senators.biospace · 1d ago
Data sources
last refreshed 3h ago
Found something off?
comments(0)
5-min edit window · permanent after that